Cough News and Research

RSS

Reese Pharmaceutical chooses SYSPRO ERP for private labeling and distribution operations

SYSPRO, the leading provider of visionary, pragmatic ERP software, today announced that Reese Pharmaceutical Company has selected SYSPRO ERP (Enterprise Resource Planning) software to run its private labeling and distribution operations. Reese, based in Cleveland, Ohio, has been in business for more than a century.

19 Mar 2010

CHMP issues positive opinion recommending approval of Tarceva as monotherapy for NSCLC

OSI Pharmaceuticals, Inc. announced today that its international partner for Tarceva® (erlotinib), Roche, informed OSI that the European Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of Tarceva as monotherapy for maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with stable disease following four cycles of standard platinum-based first-line chemotherapy.

19 Mar 2010

Noscapine can be used as prophylactic treatment for prostate cancer: Study

New research has revealed a major breakthrough in the use of cough medicine ingredient noscapine as a prophylactic treatment for prostate cancer.

19 Mar 2010

H1N1 flu pandemic awareness helps Americans to be better prepared this year: Survey

With almost half of respondents saying they believe a sneeze travels eight feet or more, one might think you would be sick all the time. But a recent national survey of 1,017 U.S. adult men and women (age 18+) conducted by Matrixx Initiatives, Inc., maker of Zicam, found a majority of Americans polled surprisingly saw this cold and flu season as "about the same" (42%) or only "slightly worse" (21%) from last year, despite all the hype this past fall around H1N1.

19 Mar 2010

Call for European Cystic Fibrosis healthcare gap to be closed

A healthcare gap amounting to a ‘death sentence’ for Cystic Fibrosis (CF) children born in Eastern Europe must be closed say researchers from the EuroCareCF Coordination Action for Cystic Fibrosis.

18 Mar 2010

New specialty service at Montefiore Medical Center helps patients with drug allergies

A Westchester patient takes aspirin for pain, but develops rashes and hives. A Bronx patient with a gastrointestinal problem caused by bacteria is prescribed penicillin, then passes out. A Bronx woman is given a contrast dye for an internal diagnostic exam, then her skin peels off.

18 Mar 2010

Simple common sense behaviors can help limit the spread of H1N1 in household: Study

Simple, common sense behaviors, including having a discussion at home about how to prevent influenza, can help limit the spread of H1N1 in a household, according to a study of the initial outbreak in New York City in 2009.

17 Mar 2010

Studies examine ways to increase healthcare personnel vaccination rates through social networking

Healthcare personnel influenza immunization rates have remained low, despite recommendations from the Centers for Disease Control and Prevention (CDC) and other leading healthcare organizations that all healthcare personnel receive annual flu vaccines.

17 Mar 2010

GAVI calls meeting with existing, potential donors

The GAVI Alliance has "asked existing and potential donors to a meeting in The Hague on March 25 and 26 to challenge them to 'make a strong impact' on childhood death rates," Reuters reports. "GAVI, which is supported by the World Health Organization, the World Bank, UNICEF, the Bill & Melinda Gates Foundation and vaccine makers, says it has 40 percent of the $7 billion it needs between now and 2015 to help" immunize of millions of children in developing countries by 2015, according to the news service.

16 Mar 2010

Eisai's Dacogen five-day dosing regimen for treatment of MDS receives FDA approval

Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of bone marrow diseases that alter the production of functional blood cells.

12 Mar 2010

FDA's Advisory Committee votes 9-3 to recommend approval of Esbriet for treatment of patients with IPF

InterMune, Inc. announced today that the U.S. Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee voted 9-3 to recommend approval of Esbriet® (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function.

9 Mar 2010

NASDAQ halts trading of InterMune's common stock, FDA PADAC to discuss pirfenidone NDA

InterMune, Inc. announced that NASDAQ has today halted trading of InterMune's common stock. The Pulmonary-Allergy Drugs Advisory Committee to the U.S. Food and Drug Administration meets today to review and discuss the company's New Drug Application for pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis.

9 Mar 2010

FDA's PADAC meeting to review pirfenidone NDA: InterMune posts briefing documents

InterMune, Inc. announced today that the U.S. Food and Drug Administration (FDA) has posted briefing documents for the March 9 Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting to review the New Drug Application (NDA) for pirfenidone, InterMune's investigational drug candidate for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function. The proposed trade name for pirfenidone is Esbriet®.

5 Mar 2010

Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

Data evaluating the efficacy and safety of STELARA™ (ustekinumab) and REMICADE® (infliximab) in patients with plaque psoriasis who had an inadequate response to Enbrel® (etanercept) will be presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) in Miami, Fla., from March 5-9, 2010.

5 Mar 2010

Survey underscores need for continued efforts to combat substance abuse among teens

New survey data released today by the Partnership for a Drug-Free America and MetLife Foundation point to the need for continued efforts to combat substance abuse among teens. While there was no significant increase in the abuse of over-the-counter (OTC) cough medicines containing dextromethorphan, the 21st annual Partnership/MetLife Foundation Attitude Tracking Survey (PATS) found an overall waning in teens' negative perceptions about many drugs along with increases in abuse rates for alcohol, ecstasy, and marijuana.

3 Mar 2010

InterMune seeks European marketing approval for pirfenidone

InterMune, Inc. today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval to market pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in the European Union (EU). Currently, there are no EMA-approved treatments for IPF in the EU.

2 Mar 2010

Balloon Sinuplasty minimally invasive surgery safe for treating chronic sinusitis in children

A recently published study in the American Journal of Rhinology and Allergy demonstrates Balloon Sinuplasty™ technology to be safe when used by physicians in pediatric patients. Known as the INTACT study, this is a prospective, non-randomized, multicenter study and was sponsored by Acclarent, Inc.

2 Mar 2010

Widespread cases of flu plunge from 49 to zero

Normally, this is the peak period for the flu in the United States. But that just doesn't seem to be the case this year.

27 Feb 2010

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

At the 17th Conference on Retroviruses and Opportunistic Infections (CROI), ViiV Healthcare presented new data across its broad range of investigational and current medicines for the treatment of HIV/AIDS. Highlighted data at the conference included an oral presentation on the investigational integrase inhibitor, S/GSK1349572, as well as data presentations on SELZENTRY® (maraviroc) and EPZICOM® (abacavir/lamivudine).

24 Feb 2010

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) plus Xeloda® (capecitabine) or 5-FU and cisplatin chemotherapy extended the lives of people with inoperable or advanced stomach (gastric) cancer, compared to chemotherapy alone.

23 Feb 2010

Cough News and Research

Reese Pharmaceutical chooses SYSPRO ERP for private labeling and distribution operations

CHMP issues positive opinion recommending approval of Tarceva as monotherapy for NSCLC

Noscapine can be used as prophylactic treatment for prostate cancer: Study

H1N1 flu pandemic awareness helps Americans to be better prepared this year: Survey

Call for European Cystic Fibrosis healthcare gap to be closed

New specialty service at Montefiore Medical Center helps patients with drug allergies

Simple common sense behaviors can help limit the spread of H1N1 in household: Study

Studies examine ways to increase healthcare personnel vaccination rates through social networking

GAVI calls meeting with existing, potential donors

Eisai's Dacogen five-day dosing regimen for treatment of MDS receives FDA approval

FDA's Advisory Committee votes 9-3 to recommend approval of Esbriet for treatment of patients with IPF

NASDAQ halts trading of InterMune's common stock, FDA PADAC to discuss pirfenidone NDA

FDA's PADAC meeting to review pirfenidone NDA: InterMune posts briefing documents

Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

Survey underscores need for continued efforts to combat substance abuse among teens

InterMune seeks European marketing approval for pirfenidone

Balloon Sinuplasty minimally invasive surgery safe for treating chronic sinusitis in children

Widespread cases of flu plunge from 49 to zero

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Industry Focus eBook - Life Science Microscopy (2nd Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News